KS78
Bluelighter
- Joined
- Apr 9, 2008
- Messages
- 945
"Today, the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the U.S. Food and Drug Administration (FDA) has agreed to MAPS’ application for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD).
The purpose of the Expanded Access program is to allow early access to potentially beneficial investigational therapies for people facing a serious or life-threatening condition for whom currently available treatments have not worked, and who are unable to participate in Phase 3 clinical trials."
Source: https://maps.org/news/media/8008-pr...gram-for-mdma-assisted-psychotherapy-for-ptsd
The purpose of the Expanded Access program is to allow early access to potentially beneficial investigational therapies for people facing a serious or life-threatening condition for whom currently available treatments have not worked, and who are unable to participate in Phase 3 clinical trials."
Source: https://maps.org/news/media/8008-pr...gram-for-mdma-assisted-psychotherapy-for-ptsd